John "Jay" Schwartz, PhD - CEO and Chairman.

Dr. Schwartz received his Ph.D. in Biochemistry and Molecular Biology at New York Medical College and was a Post-doctoral fellow at the M.I.T. Department of Biology / Harvard Medical School. He served as a lab head as Research Scientist Faculty at the M.I.T. Center for Biomedical Engineering. The CEO, Dr. John 'Jay' Schwartz, was co-founder of engeneOS, Inc. a venture-backed bio-nanotechnology company with a highly successful exit through acquisition. Prior to joining AcuityBio, he was a consultant in his capacity as Director of Life Sciences at Stage1 Strategies, LLC, a strategy and management-consulting firm focused on assisting emerging technology and early stage companies to develop, grow and achieve exits for investors through strategic aqusuisition with large pharmaceutical companies.

Mark Grinstaff, PhD - Co-founder, Advisor

Dr. Grinstaff is a Professor of Biomedical Engineering and Chemistry at Boston University. He has had prior experience with small companies and currently has a medical technology (Ocular Adhesive) in human clinical trial and a second separate technology in large animal studies. Dr. Grinstaff was recently awarded Innovator of the Year by the Boston University Office of Technology Development for his record of translating innovative research from bench-to-bedside. He has published more than 100 peer-reviewed manuscripts and given more than 175 oral presentations. Dr. Grinstaff is a co-inventor of the technology.

Jesse Wolinsky, PhD - Director of Research and Development

Dr. Wolinsky holds a Ph.D. in Biomedical Engineering from Boston University and a BS in Materials Science and Engineering from the University of Florida where he specialized in Polymer Chemistry. He is a co-inventor of the technology and responsible for most of the development work of this technology. His experience includes a focus on polymer chemistry and design of new degradable materials for biomedical applications.